Cyclacel Pharmaceuticals Inc expected to post a loss of 65  cents a share - Earnings Preview

Bio Green Med Solution

25/03/2022 21:47

* Cyclacel Pharmaceuticals Inc  CYCC.OQ   CYCC.O  is
expected
to show no change in quarterly revenue when it reports 
results on March 28. 
    * ​Refinitiv's mean analyst estimate for Cyclacel
Pharmaceuticals
Inc is for a loss of 65 cents per share. For the same quarter
last year, the company reported a loss of $1.34 per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cyclacel
Pharmaceuticals Inc is $19.5​, above​ its last closing price
of $3.17. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.64       -0.65      -0.54     Beat    16.9
 Jun. 30 2021  -0.51       -0.50      -0.56     Missed  -12.8
 Mar. 31 2021  -0.48       -0.49      -0.50     Missed  -2.7​
 Dec. 31 2020  -0.51       -0.51      -1.34     Missed  -160.2
 ​​Sep.        -0.58       -0.55      -0.47     Beat    14.5
 30 2020                                                
 Jun. 30 2020  -0.47       -0.47      -0.58     Missed  -24.3​
 Mar. 31 2020  -2.80       -2.90      -1.48     Beat    49
 Dec. 31 2019  -2.40       -2.70      -2.80     Missed  -3.7
 This summary was machine generated March 25 at 21:47 GMT.  All
figures in US dollars  unless otherwise stated